Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patientâs cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEOâPVâ01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b openâlabel clinical trial for patients with metastatic melanoma, nonâsmall cell lung cancer or bladder cancer.
Source
